Pi Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Pi Therapeutics General Information

Description

Operator of a preclinical-stage pharmaceutical company intended to develop protein degradation modulators for the treatment of cancer. The company offers a unique approach to the preferential targeting of cancer cells as well as develop a proprietary cancer drug that inhibits the proteasome-interacting protein Rpn13, enabling people to access proper treatment of cancer.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2 Ilan Ramon street
  • Ness Ziona
  • Israel

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 24-Sep-2021 000.00 Completed Out of Business
4. Early Stage VC (Series B) 29-May-2019 000.00 000.00 00000 Completed Generating Revenue
3. Seed Round Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Mar-2015 Completed Pre-Clinical Trials
1. Accelerator/Incubator 12-Dec-2014 Completed Pre-Clinical Trials
To view Pi Therapeutics’s complete valuation and funding history, request access »

Pi Therapeutics Patents

Pi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019232661-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Pending 08-Mar-2018 0000000000
EP-3762366-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Inactive 08-Mar-2018 0000000000
US-20200399262-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Pending 08-Mar-2018 000000000
CA-3092797-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Pending 08-Mar-2018 C07D413/14